Alastair Clemow joins Medgenics' board
This article was originally published in Clinica
Israeli firm Medgenics has appointed Alastair Clemow to its board of directors. He will fill the seat left vacant by the death of Lord Leonard Steinberg last November (www.clinica.co.uk, 10 November 2009). Dr Clemow worked for Johnson & Johnson from 1981 until 2000 in various positions, including vice-president of worldwide business development for its Ethicon Endo-Surgery unit, and director of research and development in J&J's orthopaedic division. He has also been president and CEO of spinal specialists Gelifex and Nexgen Spine, and currently holds the same positions at Israeli tissue repair company Regentis Biomaterials. Misgav-based Medgenics' lead product is the Epodure Biopump, which is designed to deliver therapeutic proteins. It is currently in a Phase I/II trial where it is being used to manufacture erythropoietin in anaemia patients.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.